Answers are grounded in this paper and cite their sources.
This study explored the optimal culture conditions for maximizing shiga toxin production in Stx2e-producing Escherichia coli (STEC) 150229, isolated from porcine edema disease (ED), with the goal of preparing a Stx2e toxoid vaccine candidate. High cytotoxicity was observed for this strain [tissue culture cytotoxic dose 50% (10 4 TCCD 50 /100 µl)] from 48 h after incubation. Stx2e was overexpressed by transforming pStx2e A into STEC 150229, resulting in the production of recombinant Stx2e A/B complex combined with intrinsic Stx2e B. The enhanced production of Stx2e was evaluated based on the level of cytotoxicity against Vero cells. The highest cytotoxicity (10 5 TCCD 50 /100 µl) was observed with the samples of recombinant Stx2e A/B complex eluted with 500 mM imidazole at 48 h of incubation. In conclusion, the recombinant Stx2e A protein forms an active protein complex with the intrinsic Stx2e B component from STEC 150229, producing high levels of shiga toxin.
No takes yet. Share an insight, caveat, or question.
Seo et al. (2022) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: